News
ILC Therapeutics raises £3.5m to advance lead interferon drug candidate
UK-based biotech company ILC Therapeutics has announced the successful completion of a £3.5m pre-IPO funding round.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
UK-based biotech company ILC Therapeutics has announced the successful completion of a £3.5m pre-IPO funding round.